Companies › Pacira Pharmaceuticals
4 active drug programs in 16 registered trials: 5 Phase 2, 5 Phase 4, 3 Phase 1, 3 Phase 3; Immunology, Other, Gastroenterology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Triamcinolone Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Glenohumeral Osteoarthritis; Pain; Osteoarthritis, Knee; Osteoarthritis of Knee … | Dec 2026 |
| Enekinragene Inzadenovec (PCRX-201) Gene therapy encoding TNF receptor:Fc fusion protein | – | Phase 2 | Osteoarthritis (OA) of the Knee | Nov 2026 |
| FX201 (humantakinogene hadenovec) interleukin-1 receptor antagonist (IL-1Ra) gene therapy | IL1RN | Phase 1 | Osteoarthritis, Knee | Nov 2026 |
| Bupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 1 | Postoperative Pain | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06779396 | Triamcinolone | Phase 4 | Pain | Other | Mar 2025 |
| NCT06729840 | Triamcinolone | Phase 3 | Scar, Hypertrophic | Immunology | Apr 2025 |
| NCT06681688 | Triamcinolone | Phase 1 | Cataract | Ophthalmology | Jun 2025 |
| NCT07311759 | Triamcinolone | Phase 3 | Chronic Paronychia | Infectious disease | Dec 2025 |
| NCT06237153 | Triamcinolone | Phase 2 | Carpometacarpal (CMC) Osteoarthritis | Immunology | Dec 2025 |
| NCT06981767 | Triamcinolone | Phase 2 | Oral Lichen Planus | Gastroenterology | Jul 2026 |
| NCT06884865 | Enekinragene Inzadenovec (PCRX-201) | Phase 2 | Osteoarthritis (OA) of the Knee | Immunology | Nov 2026 |
| NCT04119687 | FX201 (humantakinogene hadenovec) | Phase 1 | Osteoarthritis, Knee | Immunology | Nov 2026 |
| NCT06269705 | Triamcinolone | Phase 3 | Glenohumeral Osteoarthritis | Immunology | Dec 2026 |
| NCT06478186 | Triamcinolone | Phase 4 | Osteoarthritis, Knee | Immunology | Dec 2026 |
| NCT06271265 | Bupivacaine | Phase 1 | Postoperative Pain | Other | Jan 2027 |
| NCT06782529 | Triamcinolone | Phase 4 | Osteoarthritis of Knee | Immunology | Jan 2027 |
| NCT06782529 | Triamcinolone | Phase 4 | Osteoarthritis of Knee | Immunology | Jan 2027 |
| NCT07714525 | Triamcinolone | Phase 2 | Chronic Rhinosinusitis (CRS) | Respiratory | May 2027 |
| NCT04641351 | Triamcinolone | Phase 4 | Osteoarthritis, Knee | Immunology | Aug 2027 |
| NCT07151417 | Triamcinolone | Phase 2 | Knee Osteoarthritis | Immunology | Aug 2027 |
Cash and short-term investments of $296m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BioCryst Pharmaceuticals Arcutis Biotherapeutics Spyre Therapeutics Teva Branded Pharmaceutical Products R&D Mirador Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.